Safety and Efficacy of Baricitinib in Patients Receiving Conventional Synthetic Disease-Modifying Antirheumatic Drugs or Corticosteroids
Abstract Introduction This study assessed if concomitant use of conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) or corticosteroids altered the response or safety outcomes to baricitinib in rheumatoid arthritis (RA) patients. Methods Patients with ≥ 6 swollen/tender joints and...
Main Authors: | Ronald van Vollenhoven, Cameron Helt, Vipin Arora, Jinglin Zhong, Ana Pinto Correia, Inma de la Torre, David Muram |
---|---|
Format: | Article |
Language: | English |
Published: |
Adis, Springer Healthcare
2018-10-01
|
Series: | Rheumatology and Therapy |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1007/s40744-018-0128-0 |
Similar Items
-
Sustained Long-Term Retention Rates of Abatacept in Combination with Conventional Synthetic Disease-Modifying Antirheumatic Drugs in Elderly Patients with Rheumatoid Arthritis
by: Shuzo Sato, et al.
Published: (2021-08-01) -
Temporary interruption of baricitinib: characterization of interruptions and effect on clinical outcomes in patients with rheumatoid arthritis
by: Paul Emery, et al.
Published: (2020-05-01) -
The RA-BE-REAL Multinational, Prospective, Observational Study in Patients with Rheumatoid Arthritis Receiving Baricitinib, Targeted Synthetic, or Biologic Disease-Modifying Therapies: a 6-Month Interim Analysis
by: Rieke Alten, et al.
Published: (2022-10-01) -
Immunogenicity of Sarilumab Monotherapy in Patients with Rheumatoid Arthritis Who Were Inadequate Responders or Intolerant to Disease-Modifying Antirheumatic Drugs
by: Alvin F. Wells, et al.
Published: (2019-05-01) -
Initiation Patterns of Disease‐Modifying Antirheumatic Drugs That Have Potential to Exacerbate Heart Failure
by: Su Been Lee, et al.
Published: (2023-07-01)